Oct. 30, 2024
The pharmacy prior authorization program encourages safe, cost‑effective medication use by allowing coverage when certain conditions are met. A clinical team of physicians and pharmacists develops and approves the clinical programs and criteria for medications that are appropriate for PA by reviewing FDA-approved labeling, scientific literature, and nationally recognized guidelines.
See below for upcoming changes to the standard pharmacy PA programs. These changes affect members with prescription drug benefits administered by Prime Therapeutics.
Effective Date |
PA Program |
Description of Change |
Drug Lists |
PA or Specialty PA |
Jan. 1, 2025 |
Agamree Emflaza PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 Health Insurance Marketplace, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Androgens Anabolic Steroids PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
PA |
Jan. 1, 2025 |
Antifungals PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
PA |
Jan. 1, 2025 |
Biologic Immunomodulators PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Dry Eye Disease PAQL (formerly Ophthalmic Immunomodulators) |
Name change, new criteria requirements, new program targets |
Basic, Basic Annual, Enhanced and Enhanced Annual |
PA |
Jan. 1, 2025 |
Duvyzat PAQL |
New program |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Enspryng PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Fabhalta PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Filsuvez PA |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Korlym PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Onychomycosis PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Performance and Performance Annual |
PA |
Jan. 1, 2025 |
Oral Tetracycline Derivatives PA |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Performance and Performance Annual |
PA |
Jan. 1, 2025 |
Primary Biliary Cholangitis PAQL (formerly Ocaliva) |
Name change, new criteria requirements, new program targets |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Procysbi PA |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Pyrukynd PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Resmetirom PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
SA Oncology PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Vasomotor Symptoms PAQL (formerly Neurokinin Receptor Antagonists) |
Name change, new criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
PA |
Jan. 1, 2025 |
Verkazia PAQL (formerly included in Ophthalmic Immunomodulators) |
Name change, new criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
PA |
Jan. 1, 2025 |
Voydeya PAQL |
New program |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Vtama PA |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
PA |
Jan. 1, 2025 |
Winlevi PA |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Performance and Performance Annual |
PA |
Jan. 1, 2025 |
Xolremdi PAQL |
New program |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Zilbrysq PAQL |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
Specialty PA |
Jan. 1, 2025 |
Zoryve PA |
New criteria requirements |
Basic, Basic Annual, Enhanced, Enhanced Annual, 2024 HIM, 2025 HIM, Balanced, Performance, Performance Annual and Performance Select |
PA |
Refer to our Prior Authorization and Step Therapy Programs page for a list of programs and target drugs, the PA request form and related information.
Treatment decisions are always between you and your patients. Coverage is subject to the terms and limits of your patients’ benefit plans. Please advise them to review their benefit materials for details.
If your patients have any questions about their pharmacy benefits, they can contact the number on their member ID card. They can also visit our member site and log in to Blue Access for MembersSM or MyPrime.com for helpful tools and resources.
Prime Therapeutics LLC is a separate company contracted by Blue Cross and Blue Shield of Illinois to provide pharmacy solutions. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics. MyPrime.com is a pharmacy benefit website offered by Prime Therapeutics LLC.
The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member’s certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.
Checking eligibility and benefits and/or obtaining prior authorization is not a guarantee of payment of benefits. Payment of benefits is subject to several factors, including, but not limited to, eligibility at the time of service, payment of premiums/contributions, amounts allowable for services, supporting medical documentation, and other terms, conditions, limitations, and exclusions set forth in the member’s policy certificate and/or benefits booklet and or summary plan description. Regardless of any prior authorization or benefit determination, the final decision regarding any treatment or service is between the patient and the health care provider. If you have any questions, call the number on the member's ID card for BCBSIL.